<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239951</url>
  </required_header>
  <id_info>
    <org_study_id>MT-04</org_study_id>
    <nct_id>NCT03239951</nct_id>
  </id_info>
  <brief_title>Study to Assess the Tolerability, Safety and Efficacy of (iTIND)</brief_title>
  <official_title>Randomized, Controlled, Multi-Center Prospective Study to Assess the Tolerability, Safety and Efficacy iTIND in Subjects With Acute Urinary Retention Secondary to Benign Prostatic Obstruction (BPO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medi-Tate Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medi-Tate Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with AUR secondary to BPO that comply with Inclusion/Exclusion Criteria.

      A total of 44 eligible subjects will be randomized into the study to receive treatment with
      either re-catheterization OR with iTind implantation using a 1:1 randomization scheme
      stratified by center.

      Study duration will be 12 months post implantation, with follow-up extension of up to 3
      years. Extension of follow up period will not require an additional ICF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to void without catheter</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients with acute retention will do a trail without Catheter and if they are able to pass urine - this will be a success.the measurement is binary either can or cannot pass urine without catheter.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>temporary implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iTind</intervention_name>
    <description>temporary implant</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SOC</intervention_name>
    <description>re-catheterization</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with AUR secondary to BPH

          -  Age ≥40 years

          -  Non-responders to medical treatment :

          -  Subjects with one voiding trial failure (α-blocker consumption for at least 3 days
             prior to trial without catheter)

          -  Ability to sign an informed consent form

          -  Prostate volume &lt; 80 ml

          -  Life expectancy &gt;1 year.

          -  No active symptomatic urinary tract infection

        Exclusion Criteria:

          -  Suspected malignant disease of the lower urinary tract including prostate or bladder
             cancer

          -  Chronic retention of urine with history of either retention volume greater than one
             liter or upper tract obstruction

          -  Known neurogenic bladder

          -  Systemic anticoagulation (antiplatelet drugs allowed) which cannot be stopped for the
             procedure

          -  Immunosuppression

          -  Suspected urethral strictures, bladder neck contracture, Urinary bladder stones

          -  An active symptomatic urinary tract infection.

          -  Enrolled in another treatment trial for any disease

          -  Previous pelvic irradiation or radical pelvic surgery

          -  Any previous prostate surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King's college</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordon Muir, MD</last_name>
      <phone>0203 299 1107</phone>
      <email>gordonhmuir@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

